A previously developed physiologically based pharmacokinetic model for hepatic transporter substrates was extended to an organic anion transporting polypeptide substrate, telmisartan. Predictions used in vitro data from sandwich culture human hepatocyte and human liver microsome assays. We have developed a novel method to calibrate partition coefficients (Kps) between nonliver tissues and plasma on the basis of published human positron emission tomography (PET) data to decrease the uncertainty in tissue distribution introduced by in silico-predicted Kps. With in vitro data-predicted hepatic clearances, published empirical scaling factors, and PET-calibrated Kps, the model could accurately recapitulate telmisartan pharmacokinetic (PK) behavior before 2.5 hours. Reasonable predictions also depend on having a model structure that can adequately describe the drug disposition pathways. We showed that the elimination phase (2.5-12 hours) of telmisartan PK could be more accurately recapitulated when enterohepatic recirculation of parent compound derived from intestinal deconjugation of glucuronide metabolite was incorporated into the model. This study demonstrated the usefulness of the previously proposed physiologically based modeling approach for purely predictive intravenous PK simulation and identified additional biologic processes that can be important in prediction.
Introduction
Predicting plasma and tissue pharmacokinetic profiles in human is a critical step during drug discovery. Several attempts have been made to predict drug disposition through physiologically based pharmacokinetic (PBPK) modeling incorporating in vitro data. PBPK models offer the opportunity to characterize the underlying biologic processes and, hence, have the potential to improve prediction accuracy. Typically, generic PBPK models assume flow-limited distribution and well stirred tissue kinetics. Successful predictions using these PBPK models have been made for lipophilic compounds whose absorption and distribution are governed by passive processes (Jones et al., 2006 (Jones et al., , 2011 Rostami-Hodjegan and Tucker, 2007) . However, these models would not be expected to provide reasonable predictions for compounds that are actively transported. To improve predictions for transporter substrates, in vitro assays assessing active processes have been developed, and the active uptake rates estimated from these assays have been integrated into PBPK models (Poirier et al., 2009; Watanabe et al., 2009; Jamei et al., 2014) . In these models, reasonable predictions for substrates of liver transporters are achieved only when empirical in vitro-to-in vivo extrapolation scaling factors (SFs) are applied. Previously, our group has developed a liver transporter PBPK model and a unified set of SFs for hepatic uptake, passive diffusion, and biliary and metabolic clearances, which adequately describe the human pharmacokinetics (PK) of seven structurally diverse organic anion-transporting polypeptide (OATP) substrates, solely on the basis of in vitro sandwich culture human hepatocytes (SCHH) and human liver microsome (HLM) data Li et al., 2014) .
The aim of this study is to predict the human PK of an OATP substrate not previously evaluated by deriving the relevant hepatic clearance parameters from in vitro data and using the previously estimated empirical SFs for those clearances within the PBPK framework. Telmisartan, a potent, long-acting, small-molecule antagonist of the angiotensin II type-1 receptor (Wienen et al., 2000) , was chosen as the compound in this study because it is an OATP substrate with clinical intravenous infusion data not included in our previous work Li et al., 2014) . It has been reported to be predominantly transported into liver by OATP1B3 (encoded by the SLCO1B3 gene) (Ishiguro et al., 2006) and metabolized by UDPglucuronosyltransferase 1A3 (Ieiri et al., 2011) , with negligible biliary and renal clearance of parent (Stangier et al., 2000a) . Multiple clinical data (Stangier et al., 2000a,b) are available to evaluate predictions. To help with the analysis, we split the time course into the infusion and distribution phase (from 0 to 2.5 hours) and the elimination phase (after 2.5 hours).
During the infusion and distribution phase, Kp values, governing tissue distribution, had a major impact on plasma PK prediction. To estimate Kp, we translated the total energy absorbed by human tissues as reported in the positron emission tomography (PET) study (Shimizu et al., 2012) into tissue concentrations, as the total energy emitted from radiolabeled compound is a function of the amount in the tissues. Human plasma PK predictions with in silico Kp values were compared with the prediction using the PET Kp values. Deconjugation of glucuronide metabolite and enterohepatic recirculation of parent were added to the PBPK model to account for the long half-life observed in telmisartan clinical data.
Materials and Methods

Modeling and Simulations of Plasma PK during the Infusion and Distribution Phase
In Vivo Model. A previously published intravenous PBPK model (Li et al., 2014 ) was used to model the in vivo data. All compartments are connected by the circulating blood system. Telmisartan distribution in the liver and the two non-liver tissues with the largest volume (i.e., adipose and muscle) is assumed to be permeability limited. The liver is modeled with five pairs of subcompartments for liver blood (extracellular) and tissue (intracellular), whereas the adipose and muscle are modeled with one pair of extracellular and intracellular subcompartments. Telmisartan distribution in other tissues is assumed to be perfusion limited. Renal clearance was set to zero following a previous report (Stangier et al., 2000a) . In vitro unbound active uptake clearance (CL int, u, act ), unbound passive distribution clearance (CL int, u, pass ), and unbound biliary clearance (CL int, u, bile ) for telmisartan, as well as unbound biliary clearance for telmisartan glucuronide (CL int, u, bile, glu ) were estimated from SCHH using a mechanistic model described in the following section. In vitro unbound metabolic clearance (CL int, u, met ) was estimated using HLM data. These in vitro clearances were physiologically scaled as described previously (Houston, 1994) . Empirical SFs for OATP substrates were those estimated in the previous study, in which the active (SF act ), passive (SF pass ), metabolic (SF met ), and biliary (SF bile ) scaling factors are 55, 0.092, 0.11, and 0.019, respectively (Li et al., 2014) . The product of physiologically scaled clearance and the previously derived empirical SF is the in vivo clearance applied for in vivo simulation.
The following equations were added to the above PBPK model to predict the concentration of glucuronide in liver tissue (C IC, glu ) and residual liver bile (C bile, glu ), and the concentration of telmisartan in the residual liver bile (C bile, tel ): 
where f u, liver, tel and f u, liver, glu are the unbound fraction of telmisartan and glucuronide in the liver tissue. SCL u,bile , SCL u,met , and SCL u, bile, glu are the physiologically scaled CL int, u, bile , CL int, u, met of unbound telmisartan, and CL int, u, bile, glu of telmisartan glucuronide. SF bile, glu is the biliary scaling factor for the glucuronide. Its value is either assumed to be the same as SF bile , or was calibrated by fitting the total amount of telmisartan and telmisartan glucuronide in the liver observed in the PET study (Shimizu et al., 2012) . V bile and Q liver, bile are the volume of bile ducts in the liver and the bile flow rate. V bile and Q liver, bile were set to previously reported values, i.e., 0.318% of liver volume (Casali et al., 1994) and 350 ml/d (Davies and Morris, 1993) , respectively. MW glu and MW tel are the molecular weight of telmisartan glucuronide (690.76 g/mol) and telmisartan (514.62 g/mol). Kp Calculation. Kp is defined as
Owing to the rapid equilibrium in the postdistributional phase, the ratio between tissue concentration [C tissue (t)] and plasma concentration [C plasma (t)] at any time t is assumed to be Kp tissue .
We calculated Kp tissue from the previously published absorbed dose in each tissue (A tissue ) in the PET study (Shimizu et al., 2012) and the plasma concentration time course. The time-dependent molar concentration of drug in plasma, C plasma ðtÞ, is estimated using a previously published three-compartment population pharmacokinetic model (Wallenstein et al., 1999) .
The mean administered dose in the PET study is 1.05 mg (2.043 Â 10 29 moles). If one assumes that every telmisartan compound had been labeled with one 11 C, the number of 11 C disintegrations per unit time or total radioactivity (V) of that dose would be 6.972 Â 10 5 MBq:
where N dose is molar amount of the dose, N A is Avogadro's number, and l is the decay constant of 11 C. As the observed mean injected activity was 106.2 MBq, this indicates that most of the dose is in fact unlabeled. The ratio of labeled telmisartan at t = 0 to total telmisartan dose is:
where R is the ratio of the amount of radiolabeled molecules (N 11C ) to N dose . This value is similar to a reported typical value of only 1 in 1000 molecules labeled with 11 C for PET studies (Schlyer, 2004) . N 11C [and therefore the ratio RðtÞ] decreases because of radioactive decay according to the standard first-order radioactive decay process:
By accounting for the volume of the tissue (V tissue ) and rearranging (eq. 2), one can derive an expression for the total amount of drug in the tissue (N tissue ) at some time t:
Since the decay rate is independent of tissue, this can be converted to the amount of 11 C labeled drug in the tissue of interest using eq. (5):
The total number of 11 C disintegrations, D, in the tissue over the time course T of the experiment is expected to be:
For each 11 C disintegration, two positrons are generated and immediately annihilated releasing kjoules of energy, where for dual positron annihilation, k ¼ 1:637 Â 10 2 13 J. This implies that the total energy per kg tissue (the absorbed dose A tissue ) during the time course T of the experiment must be:
where W tissue represents the weight of the tissue. Rearranging, one can derive an expression for Kp in terms of the absorbed dose and the plasma PK:
If one makes the assumption that tissue density is approximately 1 g/cm 3 , (eq. 10) can be simplified yielding:
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The PET-derived Kp tissue values are corrected for residual blood in the tissue:
where volumes of tissues (V tissue ) and residual blood (V blood ) are obtained from (Shah and Betts, 2012) and R B/P is the blood-to-plasma ratio of telmisartan (Table 1) .
To test the models against literature PK data, the volume of distribution at steady state (Vd ss ) can be estimated from the derived Kp values as follows:
where V P and V E are volumes of plasma and erythrocytes (Shah and Betts, 2012) , R E/P is the erythrocyte/plasma concentration ratio (Table 1) . For comparison, Kp values were also predicted using a standard in silico method (Rodgers and Rowland, 2006) . In Vitro Clearance Estimation Using SCHH Assay.
Materials. In VitroGro-HT (thawing), In VitroGro-CP (plating), and In VitroGro-HI (incubation) hepatocyte media were purchased from Celsis In Vitro Technologies Inc. (IVT, Baltimore, MD). Hanks' balanced salt solution (HBSS) was purchased from Invitrogen (Carlsbad, CA). BioCoat 24-well plates and Matrigel were purchased from BD Biosciences (Bedford, MA). The BCA Protein Assay Kit was purchased from Pierce Biotechnology (Rockford, IL). High-performance liquid chromatography-grade acetonitrile and water were obtained from Honeywell Burdick & Jackson (Muskegon, MI) and Mallinckrodt Baker (Phillipsburg, NJ), respectively. Telmisartan and telmisartan acyl-b-D-glucuronide were purchased from Sequoia Research Products (Pangbourne, UK) and Toronto Research Chemicals Inc. (Ontario, Canada), respectively. All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Cryopreserved human hepatocyte lot 310 was purchased from BD Biosciences (Woburn, MA), and HU4241 was purchased from Cellzdirect (Pittsboro, NC).
Experimental procedure. Plateable cryopreserved hepatocytes (310 and HU4241) were thawed and plated as described previously (Bi et al., 2006) . Briefly, hepatocytes were thawed in a water bath at 37°C and placed on ice. The cells were then poured into In VitroGro-HT medium at 37°C at a ratio of one vial/50 ml in a conical tube. The cells were centrifuged at 50g for 3 minutes and resuspended at 0.75 Â 10 6 cells/ml in In VitroGro-CP medium. Cell viability was determined by Trypan blue exclusion. On day 1, hepatocyte suspensions were plated in collagen-coated 24-well plates at a density of 0.375 Â 10 6 cells/well in a volume of 0.5 ml/well. After 18-24 hours of incubation at 37°C, cells were overlaid with ice-cold 0.25 mg/ml Matrigel in In VitroGro-HI medium at 0.5 ml/well. Cultures were maintained in In VitroGro-HI medium that was refreshed every 24 hours. On day 5 of SCHH, the hepatocytes were first rinsed twice with Ca 2+ /Mg 2+ -containing or -free (containing 1 mM EGTA for free) HBSS buffer, and then preincubated for 10 minutes with Ca 2+ /Mg 2+ -containing HBSS, Ca 2+ /Mg 2+ -free HBSS containing 1 mM EGTA, or Ca 2+ /Mg 2+ -containing HBSS buffer in the presence of 100 mM rifamycin SV. After aspirating the preincubation buffer, 0.5 ml of incubation buffer containing substrate was added in the absence or presence of rifamycin SV. The uptake was terminated at a designated time (0.5, 1, 2, 5, 10, 15 and 20 minutes) by adding 0.5 ml of ice-cold Ca 2+ /Mg 2+containing HBSS buffer after removal of the incubation buffer. Cells were then washed three times with 0.5 ml of ice-cold Ca 2+ /Mg 2+ -containing HBSS buffer. The hepatocytes were lysed with methanol containing the internal standard for liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantification.
LC-MS/MS analysis of substrates. LC-MS/MS analysis of telmisartan and telmisartan acyl-b-D-glucuronide was analyzed on an API-4000 triple quadrupole mass spectrometer (Applied Biosystem, Foster City, CA) with an atmospheric pressure electrospray ionization source (MDS SCIEX, Concord, Ontario, Canada) that was connected to an SLC-20A LC system (Shimadzu, Kyoto, Japan) and HTC PAL autosampler (LEAP Technologies, Carrboro, NC). Samples (10 ml) were injected onto a Kinetex C18 column (2.6 mm, 100 Å, 30 Â 2.1 mm, Phenomenex, Torrance, CA) and eluted by a mobile phase with initial conditions of 10% solvent B for 0.2 minutes, followed by a linear gradient of 10% solvent B to 90% solvent B over 1 minute (solvent A: 100% water with 0.1% formic acid; solvent B: 100% acetonitrile with 0.1% formic acid) at a flow rate of 0.5 ml/min. SCHH data analysis. The modeling approach used to analyze SCHH data were developed from a previously described method . Briefly, as illustrated in Fig. 1 , the model includes compartments representing the media, cells, and bile in the experiment with compound distributed among them through CL int, u, act , CL int, u, pass , CL int, u, bile , CL int, u, met , and CL int, u, bile, glu . By varying the assay conditions (adding or subtracting rifamycin SV to inhibit active uptake, adding or subtracting Ca 2+ to inhibit biliary efflux back into the cell media), the individual active clearance rates can be derived. To simplify the analysis, the amount of glucuronidated telmisartan that is either actively transported or passively permeated back into the media from cells is assumed to be negligible. This is consistent with previous findings that only a very limited amount of glucuronide is detected in the blood (Stangier et al., 2000a) . Binding constants (K B ) are used to model nonspecific binding to cells at time zero . In the presence of Ca 2+ /Mg 2+ , passive diffusion, active uptake, and metabolic clearances occur, and compounds cleared by biliary excretion are stored in bile (Fig. 1) , and the data were modeled as 
where X tel, medial , X tel, cell , and X tel, bile are the amounts of telmisartan in media, cells, and bile, in pmoles/mg protein. The observed telmisartan data with calcium, with or without rifamycin SV, are the sum of X tel, cell and X tel, bile , whereas without calcium the data are just the amount in the cells, X tel, cell . The terms X glu, cell and X glu, bile are the amounts of telmisartan glucuronide in cells and bile, in pmoles/mg of protein. The observed glucuronide data with calcium, with or without rifamycin SV, are the sum of X glu, cell and X glu, bile , whereas without calcium the data are just the amount in the cells, X glu, cell . The terms f u, tel, cell , f u, tel, media , and f u, glu, cell are the unbound fraction of telmisartan in cells, telmisartan in media, and glucuronide in cells, respectively, where f u, tel, media was assumed to be 1 because of the absence of protein in the media. V media and V cell are the volume of media and cells. When rifamycin SV was present to inhibit active uptake clearance ( Fig. 1) , an inhibited metabolic clearance (F inhibition Â CL int, u, met ) was used to represent potential inhibition of glucuronidation by rifamycin SV observed in the current study and a previous study (Gan et al., 2010) : 
With Ca 2+ /Mg 2+ -free media, compounds cleared by biliary excretion are released into media from the bile (Fig. 1) , and the data were modeled as
The model was implemented in MATLAB (version 7.11, 2010b, MathWorks, Natick, MA). With the model and observed amounts in SCHH, CLs were estimated by simultaneously fitting telmisartan and glucuronide data under different conditions using pattern search, a global optimization method (Global Optimization Toolbox, version 3.1, MathWorks). Mean values of the parameters are estimated by simultaneously fitting all data. The coefficients of variation (CV) are calculated using values estimated in individual fitting of each replicate.
Modeling and Simulations of Plasma PK during Elimination Phases
In Vivo Model. The previously published PBPK model can adequately describe the human plasma elimination-phase profiles for four compounds with metabolic clearance (i.e., bosentan, fluvastatin, cerivastatin, and repaglinide) (Li et al., 2014) . The HLM CL int, u, met values for these compounds are 22, 29, 76, and 128 ml/min per milligram, respectively , smaller than the value for telmisartan [395 ml/min per milligram microsomal protein with bovine serum albumin (Gill et al., 2012) , 1212 ml/min per milligram microsomal protein with bovine serum albumin (this study)]. However, their mean half-lives (3.4, 1.78, 1, and 1.2 hours, respectively) are much shorter than that of telmisartan (20 hours) (Lindahl et al., 1996; Weber et al., 1996; Muck et al., 1997; Stangier et al., 2000b; Niemi et al., 2005) . To address the inconsistency between in vitro and in vivo observations, we hypothesize that telmisartan glucuronide is converted by intestinal microflora into telmisartan, and telmisartan experiences enterohepatic recirculation. Additional terms for the deconjugation of the telmisartan glucuronide in the gastrointestinal (GI) tract and enterohepatic recirculation of telmisartan were incorporated into the previously published PBPK model (Fig. 2) , accounting for the slow elimination phase of telmisartan (time course after 2.5 hours):
where X lumen, tel is the amount of telmisartan in GI lumen compartment, k a is the absorption rate, and k e is the fecal excretion rate. The sum of k a and k e is calculated as k a divided by F a , where F a is the fractional absorption of active drug. In this model, we assume that there is no glucuronidation in the GI tract, so the fraction that escapes from metabolism in the gastrointestinal tract is assumed to be 1. We assumed conversion from telmisartan glucuronide to telmisartan in this compartment is effectively instantaneous, considering almost no glucuronide was observed in feces (Stangier et al., 2000a) 
where V gut is the volume of gut tissue, Q gut is the blood flow, C a, tel is the telmisartan concentration in arterial blood, C gut, tel is the telmisartan concentration in gut compartment, and Kp gut, tel is the tissue-to-plasma partition coefficient of telmisartan.
Local Sensitivity Analysis. Local sensitivity analyses were conducted as described before using a numerical approach to approximate the partial derivatives with respect to each parameter . Briefly, each drug-specific parameter [i.e., Kp, unbound fraction in plasma (f u, p ), R B/P , f u, liver , f u, liver, glu , CL act , CL pass , CL met , CL bile , CL bile, glu , passive clearance in adipose and muscle (k a and F a )] was raised by 1% with respect to its value in the above simulation and the values of the plasma concentration, AUC plasma , and the amount of telmisartan and glucuronide in the liver were obtained throughout the time course. Sensitivity coefficients were normalized to both the parameter value and the model output value, so when the output changes by 1% for a 1% change in the input parameters, the sensitivity coefficient is 1 or 21. Only parameters with normalized sensitivity coefficients greater than 0.3 or less than 20.3 are reported.
Results
Predicted and Experimentally Determined Kps
The Kp values calculated from human PET data (Table 2) can be compared with those predicted from a standard in silico method. Since the absorbed dose in adipose was not available from the published PET study, we used the Rodgers and Rowland (2006) adipose Kp for all the simulations. The PET bone Kp was calculated from the tissueweight weighted average of the red marrow and osteogenic cells PET data. The PET gut Kp was calculated from the tissue weight-weighted average of the large and small intestine wall PET data. Lastly a "rest of body" Kp was calculated from the tissue weight-weighted average of PET data in pancreas, thymus, and other tissues.
Estimated V dss using Kp and observed plasma concentrations are given in Table 2 . In comparison with the in silico approach, using the PET Kp values leads to a Vd ss that is closer to clinical values, though both sets of Kp values result in Vd ss less than the reported clinical value. This may be attributable to enterohepatic recirculation substantially influencing the plasma concentrations after 2.5 hours as analyzed below (Miura et al., 2009; Ieiri et al., 2011) .
In Vitro SCHH Assay
The in vitro SCHH data and the model fit are shown in Fig. 3 . This assay was performed with two donors (HU4241 and BD310), but telmisartan glucuronide was not monitored in donor BD310. For this reason CL int,u,met (3.73 ml/min per 10 6 cells with CV of 24%) was fixed at the value estimated from donor HU4241. This value is close to a previously published value (4.3 ml/min per 10 6 cells) estimated from cryopreserved human hepatocytes (donor HU4122) (Menochet et al., 2012) . The estimates of the in vitro SCHH CL int, u, act , CL int, u, pass , and CL int, u, bile are shown in Table 1 as the average value from the two lots.
In Vivo PK Prediction during Infusion and Distribution Phases
Prediction Using in Silico and PET Kp. With the in silico Kp values, the model overpredicts the plasma concentration before 1 hour and underpredicts it after 1 hour for both dosing regimens (Fig. 4) . Mean-squared error between data and predictions with Rodgers and Rowland (2006) Kp is 0.199. The predictions for both dosing regimens were greatly improved by using the PET Kp values (meansquared error = 0.048), although the model still overpredicts the plasma concentration reported for the 40-mg 30-minute infusion dosing. The observed and simulated values of AUC plasma with different Kp values are reported in Table 3 . The performance of PET and in silico Kp values were not compared by simulating plasma concentration after 2.5 hours, because the plasma pharmacokinetics is no longer sensitive to Kp values as shown below.
Use of the Liver PET Data for Validation of the PBPK Model. After a micro-dose, the combined total amount of telmisartan and telmisartan glucuronide in the liver observed in the PET study (Shimizu et al., 2012) and predicted by the PBPK model are shown in Fig. 5 . The total amount of telmisartan and telmisartan glucuronide in the liver was overpredicted. The prediction also reached the maximum amount (t max = 1.9 hour) later than the data (t max = 0.8 hour). Given that the published SF bile was estimated using compounds with very different structures from telmisartan glucuronide, we fixed SF act , SF pass , SF met , SF bile for telmisartan at previously published values (i.e., 55, 0.092, 0.11, and 0.019), and re-estimated the SF bile (0.254) for telmisartan glucuronide by fitting the model to the data (Fig. 5A) . The result indicates that CL bile may be underpredicted when using the previously published SF bile . Changing the value of SF bile for telmisartan glucuronide did not affect the predicted time-concentration profiles of telmisartan in plasma. Using the fitted SF bile , the predicted total liver concentration is largely glucuronide with the exception of the earliest times (Fig. 5B ).
In Vivo PK Prediction During Elimination Phase
Prediction With Enterohepatic Recirculation. The telmisartan PBPK model with the global optimal SFs substantially underpredicts plasma concentration after 2.5 hours, which suggested that a recirculation model may be needed to predict the slow elimination of telmisartan. Although including enterohepatic recirculation did not change the model prediction during the infusion and distribution phases after intravenous infusion dosing or during the adsorption phase after oral dosing, the dmd.aspetjournals.org model predictions were greatly improved during the elimination phase (i.e., after 2.5 hours) for both dosing regimens (Fig. 6 ). Adding enterohepatic recirculation has an impact on the amount of telmisartan and telmisartan glucuronide in the liver, hence the value of SF bile, glu (0.094) was recalibrated by fitting the total amount of telmisartan and telmisartan glucuronide in the liver observed in the PET study (Shimizu et al., 2012) . Values of k a (0.68 hour 21 ) and F a (0.72) were calibrated together with SF bile, glu by simultaneously fitting human plasma concentration time courses and observed PET liver data; however, they may also be estimated from published rat data (k a = 0.775 hour 21 and F a = 0.61) (Wang et al., 2009; Furukawa et al., 2012) . Plasma data after both intravenous and oral dosing were digitized from the previous publication (Stangier et al., 2000a) up to 12 hours; large errors may be introduced by digitizing small values from plots in normal space potentially impacting values after 2.5 hours. The observed and simulated values of AUC plasma with different models are reported in Table 3 .
Local Sensitivity Analysis. The sensitivities of plasma concentration profiles, AUC plasma , and the amount of parent and glucuronide in the liver were evaluated for all compound-specific parameters. A few of the parameters had normalized sensitivity coefficients greater than 0.3 or less than 20.3 (Fig. 7) . The plasma concentration is sensitive to Kp muscle , f u, p , R B/P , f u, liver, glu , CL act , CL bile, glu , and F a . AUC plasma is sensitive to f u, p , R B/P , CL act , and F a . The total amount of telmisartan and telmisartan glucuronide in the liver is sensitive to Kp gut , R B/P , f u, liver, glu , CL bile, glu , and F a .
Discussion
Whereas predicting PK of transporter substrates remains a challenge, several groups have proposed PBPK models to improve prediction by incorporating active uptake and/or biliary clearance estimated from in vitro data (Poirier et al., 2009; Watanabe et al., 2009; Jones et al., Fig. 5 . Observed and simulated amount of telmisartan and telmisartan glucuronide in the liver. (A) Summed total amount of telmisartan and telmisartan glucuronide in the liver per dosed amount of telmisartan. Circles represent the observations in the PET study (Shimizu et al., 2012) , black dashed line represents simulation when SF bile for telmisartan glucuronide is set to previously published SF bile (Li et al., 2014) , and red solid line represents simulation with fitted SF bile for telmisartan glucuronide. (B) Simulated amount of telmisartan (green dashed line) and amount of telmisartan glucuronide (blue solid line) in the liver with fitted SF bile for telmisartan glucuronide. Jamei et al., 2014) . With empirical SFs, these models provide reasonable simulations of plasma concentrations for liver OATP substrates. Here we applied our published modeling strategy for predicating the human PK of OATP substrates to a new compound.
One purpose of this study is to identify potential weak spots in the modeling approach, such as whether our ability to predict PK is confounded by inaccurate estimates of Kps and limitations of the model structure. Assessing Kp values is challenging because methods to acquire data in humans are lacking. Kp values in PBPK models available in preclinical development are usually estimated using in silico methods and tissue composition (Poirier et al., 2009; Watanabe et al., 2009; Jones et al., 2012) . Early in silico methods focused on water-lipid partitioning in tissues (Poulin and Theil, 2000) . Later methods incorporate drug interactions with extracellular proteins (Rodgers and Rowland, 2006) , leading to the improved prediction accuracy for rat Kp and volume of distribution (Graham et al., 2012) . For acids, these methods may still mispredict Kp because they ignore other possible mechanisms, including specific or nonspecific intracellular binding to protein or compound exclusion owing to membrane potential. Kp values have also been experimentally determined using rodents or predicted using an empirical regression model whose basis is the volume of distribution and/or other physiologic properties of the compound as observed in rodents (Yun and Edginton, 2013) . However, these methods rely on the rodent data and may result in misprediction in human owing to potential species differences.
In this study, a PET-based Kp calculation method is proposed to test the PBPK model performance when it is not confounded by misestimation of nonliver tissue distribution and to validate or calibrate in silico Kp prediction methods. The comparisons between in silico Kps and PET Kps were done by predicting human intravenous data without fitting, using clearance estimated from in vitro data and SFs estimated from other OATP substrates (Li et al., 2014) . In silico Kps led to overpredicted plasma concentrations during the infusion phase, presumably attributable to underpredicted distribution to tissues. Plasma concentration was underpredicted in the elimination phase possibly because overpredicted plasma concentrations in the infusion phase led to excessive clearance of plasma drug. Kp predicted from another in silico method (Poulin and Theil, 2000) , or estimated from experimental rat tissue data (U.S. Food and Drug Administration, 1998), were also tested, but led to similar misprediction in human PK (data not shown). Only the Kp values derived from the PET data were associated with reasonable predictions. It is worth noting that the PET Kp is essentially calculated as the ratio of tissue to plasma AUCs (eqs. 8 and 11), a method previously reported (Gallo et al., 1987) . We used AUC 0-1.5 hour (the duration of the PET study) to approximate equilibrium AUC, because the two simulated AUC values are close (data not shown). The predicted Kp values largely reflect nonspecific binding in the tissues, but the values derived from the PET imaging reflect combinations of nonspecific binding, passive permeability, and efflux and influx transport or clearance processes. Tissues like muscle may have limited active uptake and largely would be expected to reflect signal from the parent compound rather than glucuronide, so the PET-derived Kp more accurately estimates this than current in silico methods do. As noted in the sensitivity analysis, the muscle Kp is an important determinant of the volume of distribution reflected in the plasma concentrations, so the 5-fold higher value obtained from the PET imaging impacts the plasma predictions. By contrast, the much higher value for the PET-derived Kp for liver probably reflects a combination of influx and efflux transport and metabolism (see Fig. 5B ). Similarly, the observed radioactivity in the PET study in kidney may reflect some active uptake and, in the small intestine, release of bile, impacting those Kps. Thus, the PET-derived Kp values provide the best fit to the data through better estimates of the Kp or through compensating for activities that may not be in the model structure, e.g., active uptake in kidney for parent or glucuronide.
Although the model can accurately predict the 20-minute infusion-40-mg human intravenous data, it still overpredicts 30-minute infusion-40-mg human intravenous data, reflecting inconsistencies between these two studies. The discrepancy between the predictions and data may be attributable to experimental factors including differences in OATP or UDP-glucuronosyltransferase polymorphic forms in the study participants (Ieiri et al., 2011; Yamada et al., 2011) versus the forms in the hepatocytes used in vitro, as well as culturing or other factors in the in vitro studies or analytical differences in the in vivo studies.
To account for the slow rate of telmisartan loss during the elimination phase despite the high metabolic clearance predicted from in vitro studies, deconjugation of glucuronide and enterohepatic circulation of parent were added into the generic model. Contradictory information about telmisartan enterohepatic recirculation has been reported. Stangier et al. (2000a) claimed that there was no evidence of enterohepatic circulation. However, direct evidence was observed in rats (U.S. Food and Drug Administration, 1998), and two groups claimed that double peaks observed in human plasma concentration-versus-time profiles suggested recirculation occurring and contributing to the long elimination half-life (Miura et al., 2009; Ieiri et al., 2011) . Telmisartan has an apparent volume of distribution 30 times higher than that of most other acidic compounds [around 7 l/kg versus 0.22 l/kg as the median value of 159 acidic compounds (Obach et al., 2008) ]. The high apparent volume of distribution and low clearance are characteristics of compounds with efficient and dominant enterohepatic recirculation (Roberts et al., 2002) . However, efficient recirculation requires efficient biliary excretion (Roberts et al., 2002) , which is not observed for telmisartan in SCHH in this study. On the contrary, a high biliary excretion rate is observed for telmisartan glucuronide in SCHH, which is consistent with previous hypotheses that in human, as in other species, telmisartan is excreted in bile as the glucuronide (Wienen et al., 2000) . Only limited glucuronide has been detected in plasma and feces, which is believed to be attributable to very efficient cleavage of glucuronide in the intestine by bacterial glucuronidases (Stangier et al., 2000a; Wienen et al., 2000) . With all this information, it appears that telmisartan enterohepatic recirculation is achieved by efficient biliary excretion and deconjugation of glucuronide. Such recirculation has been reported for other compounds with prolonged elimination and their conjugates, the topoisomerase I inhibitor 49:6, 7] indolizino [1,2-b] quinolone-3,14(4H,12H)dione] and its glucuronide (Kuhn, 1998) and 2fluoro-b-alanine and its bile acid conjugates (Zhang et al., 1993) . With k a and F a estimated from either rat or human oral data, the enterohepatic circulation of parent compound derived from deconjugation of glucuronide enables the model to accurately simulate the plasma concentration-time course from 0 to 12 hours after either intravenous or oral dosing. To predict intestinal deconjugation of glucuronide and resultant enterohepatic recirculation before a clinical study, assays that can quantify the glucuronide cleavage rate by intestinal bacterial glucuronidases are required in future. The empirical scaling factor for biliary clearance of glucuronide calibrated by PET data in this study was 5-13 times larger than our published biliary scaling factor. This may be attributable to the fact that the molecular structure, solubility, and other properties of the glucuronide are very different from the OATP substrates from which the empirical scaling factor was estimated.
In the sensitivity analysis, plasma concentration, AUC plasma , and liver amount are increasingly sensitive to F a as time increases, probably driven by the enterohepatic recirculation. The plasma concentration is sensitive to Kp muscle until about 2.5 hours, which indicates Kp values have a major impact during the distribution phase but not in the elimination phase. The total amount of telmisartan and its glucuronide in the liver is more sensitive to CL act (the max value of the normalized sensitivity coefficient is 0.22, hence this parameter is not shown in Fig.  7) than F a , f u, liver, glu , and CL bile, glu in the distribution phase, however less sensitive to CL act than the other three parameters during the elimination phase. These results indicate that predictions have different sensitivity to parameters between the distribution and elimination phases, supporting our two-step modeling scheme.
In summary, a PBPK model of telmisartan and telmisartan glucuronide was developed. Parameterized with appropriate Kp values, the PBPK model was able to predict the early intravenous plasma concentration of telmisartan without fitting. A prediction of the liver amount of telmisartan and telmisartan glucuronide was made and calibrated with PET data. Enterohepatic circulation was proposed and tested using the model to explain the flat and extended elimination phase for telmisartan. This study demonstrated usefulness of the previously proposed PBPK modeling approach for intravenous PK prediction, and identified additional factors that should be considered in predictions on future OATP substrates.
